coteauBeta Get App

LXRX

Lexicon Pharmaceuticals, Inc.
$1.49
-4.49% Oct 22 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-24%+4%+31%+59%+86%Oct 2025Oct 2026Apr 202652w high $2.6852w low $1.10
LXRXSPY
1W
-9.7%
1M
-31.7%
3M
-35.2%
6M
-11.3%
YTD
+29.6%
1Y
+7.2%

Live chart

Loading live chart…

What they do

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for LXRX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
GlobeNewswire · Oct 21
Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress
Simply Wall St. · Oct 02
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Motley Fool · Sep 28
Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating
MT Newswires · Sep 28
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
Investing.com · Sep 28

Key stats

Market value$694.1M
P/E (next 12 months, estimated)-8.2
52-week range$1.10 – $2.68
Revenue growth (latest quarter vs a year ago)-97.6%
Dividend yieldNo dividend
Analyst consensusBuy (6)
Average analyst price target$4.55 (+205%)
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

Earnings

LXRX earningsNext report in 13 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$0.05 range -$0.06–-$0.04
Revenue consensus$4.1M 6 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.06est -$0.05−24.8%Below estimates
Mar 5, 2026-$0.04est -$0.07+43.6%Above estimates
Nov 6, 2025-$0.04est -$0.07+39.4%Above estimates
Aug 6, 2025$0.01est -$0.08+112.9%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:28:46 ET
24-0824-1125-0325-0525-0825-1126-0326-08-0.190.01
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$692.0K-97.6%
2026-03-31$21.1M–
2025-12-31$5.5M–
2025-09-30$14.2M–
2025-06-30$28.9M–
Rating changes
Initiated
2026-09-28 · Cantor Fitzgerald started covering LXRX at Overweight
Reiterated
2026-05-11 · Citigroup reiterated Buy on LXRX
Reiterated
2026-03-23 · HC Wainwright & Co. reiterated Buy on LXRX
Reiterated
2026-03-10 · Citigroup reiterated Buy on LXRX
Reiterated
2026-03-05 · HC Wainwright & Co. reiterated Buy on LXRX
Reiterated
2025-09-02 · HC Wainwright & Co. reiterated Buy on LXRX

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-21 18:28:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026